Eli Lilly and Company (NYSE:LLY) Trading Up 1.6% – Here’s What Happened

Eli Lilly and Company (NYSE:LLY)’s share price was up 1.6% during trading on Monday . The company traded as high as $1,182.73 and last traded at $1,149.3790. Approximately 4,442,058 shares traded hands during mid-day trading, an increase of 38% from the average daily volume of 3,218,490 shares. The stock had previously closed at $1,131.42.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 data for its oral GLP-1 Foundayo (orforglipron), showing superior A1C reduction and weight loss versus oral semaglutide in type 2 diabetes trials. The company plans to submit the drug to the FDA by the end of the second quarter, strengthening its near-term pipeline prospects. Article: Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
• Positive Sentiment: New late-stage data for retatrutide showed broad benefits in obesity-related conditions, including meaningful weight loss and improvements in sleep apnea, knee pain, and blood sugar control. Investors see this as extending Lilly’s edge over rivals in the fast-growing weight-loss market. Article: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: Follow-up coverage from ADA and market commentary highlighted Lilly’s obesity pipeline as a major growth driver, with analysts and investors increasingly viewing the company as best positioned in GLP-1 pills and next-generation incretin therapies. Article: Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success
• Neutral Sentiment: Several articles also noted broader competitive developments, including Novo Nordisk updates and rival trial results, but the main takeaway for LLY investors is that Lilly’s own clinical data remains the dominant stock catalyst.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LLY shares. Loop Capital set a $1,200.00 price target on Eli Lilly and Company in a report on Tuesday, February 10th. Barclays boosted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, May 19th. Berenberg Bank boosted their price target on Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a report on Thursday, February 19th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,227.00.

Eli Lilly and Company Trading Up 1.6%

The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The business has a 50-day moving average of $974.59 and a 200-day moving average of $1,012.96. The firm has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.83, a P/E/G ratio of 1.24 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Norges Bank acquired a new position in Eli Lilly and Company during the fourth quarter worth approximately $12,976,634,000. Capital Research Global Investors increased its position in Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. J. Stern & Co. LLP increased its position in Eli Lilly and Company by 46,191.3% during the fourth quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after buying an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. increased its position in Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after buying an additional 2,131,734 shares during the last quarter. Finally, Fifth Third Bancorp increased its position in Eli Lilly and Company by 321.3% during the first quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.